Danaher Corporation (LON:0R2B)
London
· Delayed Price · Currency is GBP · Price in USD 226.28
-0.96 (-0.42%)
Dec 5, 2025, 4:41 PM BST
Revenue Breakdown
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 26, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Biotechnology Revenue | 7.13B | 6.76B |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Revenue | 7.28B | 7.33B |
Log In |
Log In |
Log In | Upgrade
|
| Former Life Sciences Revenue | 14.41B | 14.09B |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Revenue | 9.86B | 9.79B |
Log In |
Log In |
Log In | Upgrade
|
| Environmental & Applied Solutions Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -14.41B | -14.09B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 24.27B | 23.88B |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 26, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| North America Revenue | 10.37B | 10.30B |
Log In |
Log In |
Log In | Upgrade
|
| Western Europe Revenue | 5.74B | 5.46B |
Log In |
Log In |
Log In | Upgrade
|
| Other Developed Markets Revenue | 1.25B | 1.25B |
Log In |
Log In |
Log In | Upgrade
|
| High-Growth Markets Revenue | 6.91B | 6.87B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 24.27B | 23.88B |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 2
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 26, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Recurring Revenue | 19.91B | 19.37B |
Log In |
Log In |
Log In | Upgrade
|
| Non-Recurring Revenue | 4.36B | 4.51B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 24.27B | 23.88B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 26, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Biotechnology Operating Income | 1.83B | 1.69B |
Log In |
Log In |
Log In | Upgrade
|
| Life Sciences Operating Income | 560.00M | 879.00M |
Log In |
Log In |
Log In | Upgrade
|
| Former Life Sciences Operating Income | 2.39B | 2.56B |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Operating Income | 2.56B | 2.63B |
Log In |
Log In |
Log In | Upgrade
|
| Environmental & Applied Solutions Operating Income | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Other) | -340.00M | -326.00M |
Log In |
Log In |
Log In | Upgrade
|
| Operating Income (Total) | 4.61B | 4.86B |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2019 |
| Core Sales Growth Ex-Cytiva | - |
Log In |
Log In |
Log In | Upgrade
|
| Core Sales Growth | -1.50% |
Log In |
Log In |
Log In | Upgrade
|